Cocrystal Pharma, Inc. (COCP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 2M 4M 6M Q1 '15: 27K Q2 '15: 27K Q3 '15: 24K Q1 '16: 0 Q1 '19: 5.1M Q2 '19: 592K Q3 '19: 492K Q4 '19: 402K Q1 '20: 461K Q2 '20: 554K Q3 '20: 489K Q4 '20: 510K Q1 '26: 225K Q2 '26: 105K Q2 '15 Q1 '16 Q2 '19 Q4 '19 Q2 '20 Q4 '20 Q2 '26

Gross Profit Quarterly

0 800K 1.6M 2.4M Q1 '10: 1.8M Q2 '10: 1.6M Q3 '10: 2.1M Q4 '10: 1.2M Q1 '11: 1.3M Q2 '11: 883.2K Q3 '11: 2.1M Q1 '12: 1.4M Q2 '12: 2M Q3 '12: 1.9M Q4 '12: 2.1M Q1 '13: 592.1K Q2 '13: 551.7K Q3 '13: 1.1M Q2 '10 Q4 '10 Q2 '11 Q1 '12 Q3 '12 Q1 '13 Q3 '13

Operating Income Quarterly

-105M -70M -35M 0 35M 70M 105M Q3 '16: -1.9M Q4 '16: -94.4M Q1 '17: -3.1M Q2 '17: -2.1M Q3 '17: -2.1M Q4 '17: -1.8M Q1 '18: -2.1M Q2 '18: -2.1M Q3 '18: -2.4M Q4 '18: -56.3M Q1 '19: 2.9M Q2 '19: -1.6M Q3 '19: -1.8M Q4 '19: -47.9M Q1 '20: -2M Q2 '20: -3.5M Q3 '20: -2.7M Q4 '20: -1.5M Q1 '21: -2.7M Q2 '21: -3.8M Q3 '21: -4M Q4 '21: -3.7M Q1 '22: -4.2M Q2 '22: -24.4M Q3 '22: -5.7M Q4 '22: -4.5M Q1 '23: -5.1M Q2 '23: -4.3M Q3 '23: -4.4M Q4 '23: -4.7M Q1 '24: -4.2M Q2 '24: -5.4M Q3 '24: -5M Q4 '24: -3.2M Q1 '25: -2.3M Q2 '25: -2.1M Q3 '25: -2.1M Q4 '25: -2.5M Q1 '26: -2.4M Q2 '26: -3.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '16: -1.9M Q4 '16: -65.8M Q1 '17: -2.5M Q2 '17: -2.3M Q3 '17: -2.3M Q4 '17: 4.9M Q1 '18: -1.6M Q2 '18: -1.3M Q3 '18: -1.9M Q4 '18: -44.3M Q1 '19: 3M Q2 '19: -1.5M Q3 '19: -1.8M Q4 '19: -47.8M Q1 '20: -2M Q2 '20: -3.5M Q3 '20: -2.7M Q4 '20: -1.5M Q1 '21: -2.7M Q2 '21: -3.8M Q3 '21: -3.9M Q4 '21: -3.7M Q1 '22: -4.2M Q2 '22: -24.4M Q3 '22: -5.7M Q4 '22: -4.5M Q1 '23: -5.2M Q2 '23: -4.2M Q3 '23: -4.2M Q4 '23: -4.5M Q1 '24: -4M Q2 '24: -5.3M Q3 '24: -4.9M Q4 '24: -3.3M Q1 '25: -2.3M Q2 '25: -2.1M Q3 '25: -2M Q4 '25: -2.4M Q1 '26: -2.3M Q2 '26: -3.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-10.5M -7M -3.5M 0 3.5M 7M 10.5M Q3 '16: -3.1M Q4 '16: -2.3M Q1 '17: -2.1M Q2 '17: -1.1M Q3 '17: -2.2M Q4 '17: -1.6M Q1 '18: -2.1M Q2 '18: -2.1M Q3 '18: -2.1M Q4 '18: -2M Q1 '19: 2M Q2 '19: -1M Q3 '19: -1.3M Q4 '19: -1.2M Q1 '20: -2.2M Q2 '20: -2.2M Q3 '20: -3.1M Q4 '20: -2.4M Q1 '21: -1.8M Q2 '21: -2.6M Q3 '21: -5.4M Q4 '21: -2.9M Q1 '22: -3.9M Q2 '22: -3.7M Q3 '22: -8.9M Q4 '22: -4.9M Q1 '23: -3.1M Q2 '23: -5.5M Q3 '23: -2.7M Q4 '23: -3.3M Q1 '24: -4.5M Q2 '24: -3.7M Q3 '24: -5.1M Q4 '24: -3.2M Q1 '25: -2.9M Q2 '25: -2.2M Q3 '25: -1.4M Q4 '25: -1.7M Q1 '26: -2.3M Q2 '26: -2.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-6M -4M -2M 0 2M 4M 6M Q4 '13: -811K Q4 '14: -1.8M Q1 '15: -1.6M Q2 '15: -2.5M Q3 '15: -3.4M Q4 '15: -3.2M Q1 '16: -4.1M Q2 '16: -5.1M Q3 '16: -3.2M Q4 '16: -2.3M Q1 '17: -2.1M Q2 '17: -1.1M Q3 '17: -2.2M Q4 '17: -1.6M Q1 '18: -2.1M Q2 '18: -2.1M Q3 '18: -2.2M Q4 '18: -2M Q1 '19: 2M Q2 '19: -1M Q3 '19: -1.4M Q4 '19: -1.2M Q1 '20: -2.3M Q2 '20: -2.3M Q3 '20: -3.1M Q4 '20: -2.4M Q1 '21: -1.8M Q2 '21: -2.6M Q3 '21: -5.4M Q4 '21: -2.9M Q4 '22: -4.9M Q1 '23: -3.2M Q2 '23: -5.6M Q3 '23: -2.7M Q4 '23: -3.4M Q1 '24: -4.5M Q2 '24: -3.7M Q3 '24: -5.1M Q4 '24: -3.2M Q4 '25: -1.7M Q3 '15 Q4 '16 Q1 '18 Q2 '19 Q3 '20 Q4 '21 Q4 '23 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 250M 500M 750M Q1 '13: 57.3K Q2 '13: 57.3K Q3 '13: 70.1M Q1 '14: 324.5K Q2 '14: 326.8K Q3 '14: 327.2K Q1 '15: 439.9K Q2 '15: 696.8K Q3 '15: 696.9K Q1 '16: 697.3M Q2 '16: 705.6M Q3 '16: 707.5M Q1 '17: 23.8M Q2 '17: 24.3M Q3 '17: 728M Q1 '18: 24.4M Q2 '18: 27.7M Q3 '18: 29.9M Q1 '19: 30.4M Q2 '19: 31.6M Q3 '19: 31.6M Q1 '20: 41.7M Q2 '20: 52.1M Q1 '21: 71.3M Q2 '21: 87.1M Q3 '21: 8.1M Q1 '22: 8.1M Q2 '22: 8.1M Q3 '22: 8.1M Q1 '23: 8.1M Q2 '23: 10.1M Q3 '23: 10.2M Q1 '24: 10.2M Q2 '24: 10.2M Q3 '24: 10.2M Q1 '25: 10.2M Q2 '25: 10.2M Q3 '25: 11M Q1 '26: 13.8M Q2 '26: 13.8M Q2 '14 Q1 '16 Q3 '17 Q2 '19 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q1 '12: -0.15 Q2 '12: -0.15 Q3 '12: -0.11 Q4 '12: -0.13 Q3 '16: -0.06 Q4 '16: -3.07 Q1 '17: -3.17 Q2 '17: -3.26 Q3 '17: -3.26 Q4 '17: 0.00 Q1 '18: 0.05 Q2 '18: 0.09 Q3 '18: 0.03 Q4 '18: -1.75 Q1 '19: -1.59 Q2 '19: -1.59 Q3 '19: -1.59 Q4 '19: -1.51 Q1 '20: -1.66 Q2 '20: -1.68 Q3 '20: -1.67 Q4 '20: -0.18 Q1 '21: -0.17 Q2 '21: -0.14 Q3 '22: -4.26 Q4 '22: -4.76 Q1 '23: -4.88 Q2 '23: -2.29 Q3 '23: -2.00 Q4 '23: -1.90 Q1 '24: -1.65 Q2 '24: -1.77 Q3 '24: -1.85 Q4 '24: -1.73 Q1 '25: -1.57 Q2 '25: -1.24 Q3 '25: -0.94 Q4 '25: -0.79 Q1 '26: -0.73 Q2 '26: -0.76 Q3 '16 Q4 '17 Q1 '19 Q2 '20 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.